Physician profile
Eva Lock
NPI 1275904625
$6,634.33
in general payments reported to CMS, 2019-2025
21 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,217 · 2022: $1,366 · 2023: $1,296 · 2024: $1,430 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,052.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,924.24 | 2021-2025 | |
| Corium, LLC | $1,078.31 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $945.89 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $726.37 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $590.41 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $242.30 | 2021-2022 | |
| Novo Nordisk INC | $204.61 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $190.80 | 2023-2024 | Auvelity |
| Amgen INC. | $129.83 | 2024-2025 | Repatha, Repatha, Otezla |
| Alkermes, INC. | $93.12 | 2021-2025 | Lybalvi |
| Tris Pharma INC | $75.47 | 2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $73.38 | 2021-2023 | Jornay Pm |
| Pfizer INC. | $70.10 | 2023-2025 | |
| Lilly USA, LLC | $62.08 | 2021-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $54.03 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $51.00 | 2025 | Jornay Pm |
| Lundbeck LLC | $45.52 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $31.69 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.76 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.77 | 2025 | Airsupra |
| Genentech USA, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Lock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.